Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Advances Mid-Stage Trial of New Obesity Drug PF-07976016

Study Overview: This Phase 2a trial, officially titled “A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY,” aims to test how safe and effective PF-07976016 is for adults with obesity. The focus is on weight loss and how well people tolerate the drug, which is important as Pfizer looks to build a stronger position in the fast-growing obesity treatment market.

Intervention/Treatment: The study tests PF-07976016, a once-daily oral drug, against a once-daily placebo. The goal is to see whether PF-07976016 can deliver meaningful weight loss and an acceptable side-effect profile, positioning it as a potential competitor to current obesity treatments.

Study Design: Participants were randomly assigned to one of several dose levels of PF-07976016 or to placebo. The trial used a parallel-group design, meaning each group stayed on its assigned treatment throughout the study. Both patients and investigators were blinded to who received the active drug or placebo, while the sponsor (Pfizer) remained unblinded. The main purpose is treatment-focused: to see if PF-07976016 can safely help reduce body weight.

Study Timeline: The study was first submitted on December 2, 2024, marking the formal regulatory registration. It has already reached “Completed” status, indicating that participant treatment and follow-up are finished, although no results have been posted yet. The latest update to the listing was submitted on February 4, 2026, signaling that Pfizer is actively maintaining the record as it processes and reviews the data internally.

Market Implications: Completion of this Phase 2a trial is a key milestone for Pfizer (PFE) in its effort to secure a foothold in obesity drugs, a category currently dominated by Novo Nordisk and Eli Lilly. While no efficacy results are available yet, the update alone can support a constructive long-term narrative around Pfizer’s pipeline and help sentiment as investors look for growth beyond COVID-related revenues. If upcoming data show competitive weight-loss outcomes with manageable side effects, this program could become a meaningful value driver and narrow the perceived gap with leading players. Conversely, weak results would likely temper enthusiasm and push investors to focus back on other late-stage assets in Pfizer’s portfolio.

The study is now completed and recently updated, with further details and future results to be made available on the ClinicalTrials.gov portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.